This page lists the SEC filings reported by Astellas Pharma Inc..
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2023-08-18 | Astellas Pharma Inc. | Taysha Gene Therapies, Inc. | 7,266,342 | 3.9% | EDGAR |
| SC 13G | 2015-02-12 | Astellas Pharma Inc. | FIBROGEN INC | 4,968,367 | 8.6% | EDGAR |
| SC 13G | 2014-12-29 | Astellas Pharma Inc. | CYTOKINETICS INC | 2,040,816 | 5.3% | EDGAR |
| SC 13G/A | 2010-12-06 | Astellas Pharma Inc. | Sucampo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D | 2010-06-09 | Astellas Pharma Inc. | OSI PHARMACEUTICALS INC | 57,232,357 | 93.0% | EDGAR |
| SC 13G | 2008-02-14 | Astellas Pharma Inc. | Sucampo Pharmaceuticals, Inc. | 1,253,750 | 8.1% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.